CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 88 enrolled
Drug / intervention
bimatoprost ophthalmic solution 0.03% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01448525
NCT01448525Phase 4Completed
CompareCT.gov

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Allergan·interventional·Posted Oct 7, 2011·Updated May 22, 2013

In Brief

A Phase 4 clinical trial evaluating bimatoprost ophthalmic solution 0.03% and bimatoprost vehicle solution for Hypotrichosis. Completed, enrolled 88 participants across 1 site.

Detailed Summary

The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypotrichosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 7, 2011
Enrollment StartOct 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.7 years ago

Interventions

bimatoprost ophthalmic solution 0.03%drug

One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

bimatoprost vehicle solutiondrug

One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.